Agenus Inc. (AGEN) Given Consensus Recommendation of “Buy” by Analysts
Agenus Inc. (NASDAQ:AGEN) has earned a consensus rating of “Buy” from the seven analysts that are presently covering the company. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $12.20.
A number of equities research analysts have commented on the company. Zacks Investment Research cut Agenus from a “buy” rating to a “hold” rating in a report on Wednesday, September 28th. Jefferies Group reiterated a “buy” rating on shares of Agenus in a report on Tuesday, August 23rd. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Agenus in a report on Sunday, July 31st. Finally, Maxim Group reiterated a “buy” rating and set a $7.00 target price on shares of Agenus in a report on Thursday, July 28th.
In other news, Director Ulf Wiinberg bought 30,000 shares of Agenus stock in a transaction that occurred on Tuesday, September 6th. The shares were purchased at an average price of $6.29 per share, for a total transaction of $188,700.00. Following the completion of the acquisition, the director now owns 30,000 shares of the company’s stock, valued at $188,700. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.60% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its position in shares of Agenus by 2.8% in the second quarter. Bank of New York Mellon Corp now owns 342,133 shares of the company’s stock worth $1,385,000 after buying an additional 9,403 shares during the last quarter. venBio Select Advisor LLC boosted its position in shares of Agenus by 9.2% in the first quarter. venBio Select Advisor LLC now owns 2,400,868 shares of the company’s stock worth $9,988,000 after buying an additional 201,731 shares during the last quarter. Creative Planning boosted its position in shares of Agenus by 2.8% in the second quarter. Creative Planning now owns 64,171 shares of the company’s stock worth $260,000 after buying an additional 1,762 shares during the last quarter. Blair William & Co. IL boosted its position in shares of Agenus by 45.9% in the second quarter. Blair William & Co. IL now owns 59,700 shares of the company’s stock worth $189,000 after buying an additional 18,775 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Agenus by 2.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 983,924 shares of the company’s stock worth $3,985,000 after buying an additional 28,006 shares during the last quarter. Hedge funds and other institutional investors own 40.64% of the company’s stock.
Shares of Agenus (NASDAQ:AGEN) opened at 5.86 on Thursday. The stock’s market cap is $509.30 million. The company has a 50 day moving average price of $6.69 and a 200 day moving average price of $5.06. Agenus has a 12-month low of $2.61 and a 12-month high of $7.49.
Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, July 28th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The firm had revenue of $6.59 million for the quarter, compared to analysts’ expectations of $5.12 million. Agenus had a negative return on equity of 138.27% and a negative net margin of 328.53%. Analysts anticipate that Agenus will post ($1.27) earnings per share for the current fiscal year.
Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Stock Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related stocks with our FREE daily email newsletter.